Vaccine partnering terms and agreements

92
-1

Published on

Published in: Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
92
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Vaccine partnering terms and agreements

  1. 1. Vaccine Partnering Terms and Agreements The Vaccine Partnering Terms and Agreements report provides comprehensive understanding andunprecedented access to the vaccine partnering deals and agreements entered into by the worlds leadinghealthcare companies. Trends in vaccine and adjuvant partnering deals Deal terms analysis Partnering agreement structurePartnering contract documents Top deals by value Most active dealmakers Average deal terms for vaccinesThe report provides a detailed understanding and analysis of how and why companies enter vaccine partneringdeals. The majority of deals are discovery or development stage whereby the licensee obtains a right or anoption right to license the licensors vaccine technology. These deals tend to be multicomponent, starting withcollaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals andalliances. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insightinto the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilstmany smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms ofhow payments are triggered – contract documents provide this insight where press releases do not. This report contains over 1,500 links to online copies of actual vaccine deals and contract documents assubmitted to the Securities Exchange Commission by companies and their partners. Contract documentsprovide the answers to numerous questions about a prospective partner’s flexibility on a wide range ofimportant issues, many of which will have a significant impact on each party’s ability to derive valuefrom the deal. The initial chapters of this report provide an orientation of vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends invaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms. Chapter 3 provides a review of the leading vaccine deals since 2007. Deals are listed by headline value,signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal hasan agreement contract published at the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summaryfollowed by a comprehensive listing of vaccine deals as well as contract documents available in the publicdomain. Where available, each deal title links via Weblink to an online version of the actual contractdocument, providing easy access to each contract document on demand. Chapter 5 provides a comprehensive and detailed review of vaccine partnering deals signed and announcedsince 2007, where a contract document is available in the public domain. The chapter is organized by companyA-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specifictherapy focus. Each deal title links via Weblink to an online version of the deal record and where available, thecontract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the trends and activities in vaccinepartnering and dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in theVaccine Partnering Terms and Agreements
  2. 2. research, development and commercialization of vaccine technologies and products. Vaccine Partnering Terms and Agreements is intended to provide the reader with an in-depth understandingand access to vaccine trends and structure of deals entered into by leading companies worldwide. Vaccine Partnering Terms and Agreements includes: Trends in vaccine dealmaking in the biopharma industry since 2007 Analysis of vaccine deal structureAccess to headline, upfront, milestone and royalty data Case studies of real-life vaccine deals Access to over1,500 vaccine deal documents The leading vaccine deals by value since 2007 Most active vaccine dealmakerssince 2007 The leading vaccine partnering resources In Vaccine Partnering Terms and Agreements, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Each deal title links via weblink to an online version of the deal record and where available, the contractdocument, providing easy access to each contract document on demand. The Vaccine Partnering Terms and Agreements report provides comprehensive access to available deals andcontract documents for over 1,500 vaccine deals. Analyzing actual contract agreements allows assessment ofthe following: What are the precise vaccine rights granted or optioned? What is actually granted by the agreement to thepartner company? What exclusivity is granted? What is the payment structure for the deal? How are sales andpayments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRshandled and owned? Who is responsible for commercialization? Who is responsible for development, supply,and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Underwhat conditions can the deal be terminated? What happens when there is a change of ownership? Whatsublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the companyinsist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?table Of Contentsexecutive Summarychapter 1 – Introductionchapter 2 – Trends In Vaccine Dealmaking2.1. Introduction2.2. Vaccine Partnering Over The Years2.3. Bigpharma Vaccine Dealmaking Activity2.4. Bigpharma Not Active In Vaccine Partnering2.5. Vaccine Partnering By Deal Type2.6. Vaccine Partnering By Disease Type2.7. Average Deal Terms For Vaccine PartneringVaccine Partnering Terms and Agreements
  3. 3. 2.7.1 Vaccine Partnering Headline Values2.7.2 Vaccine Deal Upfront Payments2.7.3 Vaccine Deal Milestone Payments2.7.4 Vaccine Royalty Rateschapter 3 – Leading Vaccine Deals3.1. Introduction3.2. Top Vaccine Deals By Value3.3. Top Vaccine Deals Involving Bigpharmachapter 4 – Bigpharma Vaccine Deals4.1. Introduction4.2. How To Use Bigpharma Vaccine Partnering Deals4.3. Bigpharma Vaccine Partnering Company Profilesabbottastellasastrazenecabaxter Internationalbayerbiogen Idecboehringer Ingelheimbristol-myers Squibbcsldaiichi Sankyogilead Sciencesglaxosmithklinekyowa Hakko Kirinmerck & Comerck Kgaamitsubishi Tanabenovartispfizerrochesanofitakedachapter 5 – Vaccine Dealmaking Directory5.1. Introduction5.2. Company A-z5.3. By Stage Of DevelopmentVaccine Partnering Terms and Agreements
  4. 4. discoveryformulationmarketedphase Iphase Iiphase Iiipreclinicalregulatory5.4. By Deal Typeasset Purchaseco-developmentcollaborative R&dcontract Serviceco-promotioncradadevelopmentdistributionequity Purchasegrantjoint Venturelicensinglitigationmanufacturingmarketingmaterial Transferoptionresearchsettlementspin Outsupplytechnologyterminationwarranty5.5. By Therapy Areaimmunologyinfectivesinflammatoryrespiratory5.6. By Vaccine Technology Typechapter 6 – Vaccine Partnering Resource Center6.1. Online Vaccine PartneringVaccine Partnering Terms and Agreements
  5. 5. 6.2. Vaccine Partnering Events6.3. Further Reading On Vaccine Dealmakingabout Wildwood Venturescurrent Partneringcurrent Agreementscurrent Reportsrecent Titles From Currentpartneringorder Form – Reportsappendicesappendix 1 –vaccine Dealmaking – By Company A-zappendix 2 – Vaccine Dealmaking – By Deal Typeappendix 3 – Vaccine Dealmaking – By Stage Of Developmentappendix 4 – vaccine Dealmaking – By Therapy Areaappendix 5 – Deal Type Definitionsappendix 6 – Example Vaccine Partnering AgreementAbout Us:Transparency Market Research is a market intelligence company providing global business informationreports and services. Our exclusive blend of quantitative forecasting and trends analysis providesforward-looking insight for thousands of decision makers. We are privileged with highly experienced team ofAnalysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques togather, and analyze information. Our business offerings represent the latest and the most reliable informationindispensable for businesses to sustain a competitive edge.Contact:ResearchMoz90 State Street,Suite 700,Albany NY - 12207Vaccine Partnering Terms and Agreements
  6. 6. United StatesTel: +1-518-618-1030USA - Canada Toll Free 866-997-4948Email: sales@researchmoz.usBlog: http://researchmoz.blogspot.com/Website: http://www.researchmoz.us/Vaccine Partnering Terms and Agreements

×